Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: March 2008
-
By Christopher P. Singer — An e-Alert sent out on March 26, 2008 by the U.S. Patent and Trademark Office contained information regarding enhancements in Private PAIR 7.2, e-Office action and reminder postcards, and a quick way to link to recent e-filing acknowledgment receipts. New Private PAIR 7.2 Enhancements On March 22, 2008,…
-
By Donald Zuhn — In an Op-Ed piece appearing in last Saturday’s edition of The Boston Globe, Alnylam Pharmaceuticals Inc. Chief Executive Officer Dr. John Maraganore (at right) wrote about a "perfect storm" that is building against biomedical patent protection. In an article entitled, "Good for iPods, but bad for patients," Dr. Maraganore…
-
By Kevin E. Noonan — Biologic drugs, the pharmaceutical embodiments of biotechnology, are an important part of the current pharmaceutical armamentarium, and this is only expected to increase. There are 150 approved biologic drugs in the U.S., contributing $40 billion to U.S. drug costs in 2005; these costs are expected to increase to…
-
Patent Profile: Redpoint Bio Announces Issuance of Patent for Identifying Taste Signaling Modulators
By Donald Zuhn — Redpoint Bio Corp. announced earlier this month that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,341,842, which is directed to methods of methods for identifying modulators of the TRP8-mediated taste response. Such modulators can be used as flavor enhancers in foods, beverages, or pharmaceuticals to…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Forest Laboratories, Inc. et al. v. Synthon Pharmaceuticals, Inc. et al.5:08-cv-00150; filed March 20, 2008 in the Eastern District of North Carolina…
-
March 30-April 1, 2008 – Advanced Courses (Patent Resources Group) – Bonita Springs, FL March 31-April 1, 2008 – Document Management, E-Discovery, and Litigation Readiness (American Conference Institute) – New York, NY April 1-2, 2008 – IP Summit (Ocean Tomo) – San Francisco, CA April 3-5, 2008 – Advanced Courses (Patent Resources Group) – Bonita…
-
The U.S. Court of Appeals for the Federal Circuit will be holding a Judicial Conference entitled "The Federal Circuit: A National Court of Appeals: Addressing New Challenges" on May 15, 2008 in Washington, DC. Topics and speakers at the conference will include: • State of the Court — Chief Judge Paul Michel• Federal Circuit Rules…
-
Federal Circuit Gives Amgen a Mixed Decision on Its ITC Complaint against Roche’s Mircera® By Kevin E. Noonan — The Federal Circuit in a decision handed down on Wednesday affirmed the International Trade Commission’s grant of summary judgment against Amgen in its attempts to block importation of Roche’s Mircera® peglylated erythropoietin product. In…
-
By Kevin E. Noonan — On Tuesday, Roche filed its brief in support of U.S. District Court for the District of Massachusetts (Judge William G. Young, presiding) modifying its preliminary injunction granted on February 28th, barring Roche from launching its FDA-approved Mircera® drug product. The Court’s preliminary injunction was entered pursuant to a…
-
By Donald Zuhn — OPKO Health, Inc. announced yesterday that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,345,027, which is directed to methods of inhibiting the expression of human vascular endothelial growth factor (VEGF), degrading VEGF mRNA, inhibiting angiogenesis, or treating an angiogenic disease using a specific short interfering…
Patent Docs 